6,11-Dihydroxy-5a,7,8,9,10,11a-hexahydrotetracene-5,12-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 并四苯
• 英文名称: 6,11-Dihydroxy-5a,7,8,9,10,11a-hexahydrotetracene-5,12-dione
• 英文别名: 6,11-dihydroxy-5a,7,8,9,10,11a-hexahydrotetracene-5,12-dione
• 化学式: C₁₈H₁₆O₄
• 分子量: 296.3
• InChiKey: OFYFIAKERUJSSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
  申请人：Astellas Pharma Inc.

  公开号：EP3670537A1

  公开（公告）日：2020-06-24

  The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN 18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.

  本发明通常提供一种疗法，用于有效治疗和/或预防与表达 CLDN18.2 的细胞有关的疾病，特别是胃食管癌等癌症疾病。本发明提供的数据表明，对患有胃食管癌的人类患者施用抗CLDN18.2抗体是安全和耐受性良好的，剂量至少为1000毫克/平方米。此外，报告还提供了数据，证明该抗体在这些患者体内具有充分的功能，可发挥抗肿瘤细胞的作用，并获得了抗肿瘤活性的证据。
• COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
  申请人：Astellas Pharma Inc.

  公开号：EP3725810A1

  公开（公告）日：2020-10-21

  The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

  本发明提供了一种联合疗法，可有效治疗和/或预防与表达CLDN18.2的细胞有关的疾病，包括胃癌、食管癌、胰腺癌、肺癌、卵巢癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移瘤等癌症疾病。
• Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
  申请人：Ganymed Pharmaceuticals AG

  公开号：US10022444B2

  公开（公告）日：2018-07-17

  The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

  本发明提供了一种联合疗法，可有效治疗和/或预防与表达CLDN18.2的细胞有关的疾病，包括胃癌、食管癌、胰腺癌、肺癌、卵巢癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移瘤等癌症疾病。
• Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
  申请人：Ganymed Pharmaceuticals AG

  公开号：US10314890B2

  公开（公告）日：2019-06-11

  The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.

  本发明提供了一种联合疗法，用于有效治疗和/或预防与表达CLDN18.2的细胞有关的疾病，包括癌症疾病，如胰腺癌及其转移。
• US9433675B2
  申请人：——

  公开号：US9433675B2

  公开（公告）日：2016-09-06